Evidence map›Paper›PMID 39395753›Full record

Trial reportInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2024

Randomised immunogenicity trial comparing 2019-2020 recombinant and egg-based influenza vaccines among frequently vaccinated healthcare personnel in Israel.

Ashley L Fowlkes, Alon Peretz, David Greenberg, Avital Hirsch, Emily T Martin, Min Z Levine, Laura Edwards, Sarah Radke, Adam S Lauring, Jill M Ferdinands and 10 more

Registry-linked trialAbstract readRandomized Controlled TrialComparative Study
In one paragraph

Trial report in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04523324 (Randomized Comparison of the Immunogenicity of Recombinant and Egg-based Influenza Vaccines Among Healthcare Personnel in Israel), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04523324 phase4completednot on this map

Randomized Comparison of the Immunogenicity of Recombinant and Egg-based Influenza Vaccines Among Healthcare Personnel in Israel

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2019 to 2022Enrolled577ConditionsInfluenzaArmsFlublok™ Quadrivalent by Sanofi, Inc., VaxigripTetra™ by Sanofi, Inc.
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Comparison of the immunogenicity of adjuvanted and conventional egg-based quadrivalent influenza vaccines among healthcare personnel in Lima, Peru: A randomized controlled trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
    Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Ashley L FowlkesInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Electronic address: Ahl4@cdc.gov.
Alon PeretzRabin Medical Center, Clalit Health Services, Beilinson Campus, Petah Tikva, Israel.
David GreenbergSoroka University Medical Center, Clalit Health Services, Be'er Sheva, Israel.
Avital HirschClalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.
Emily T MartinSchool of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
Min Z LevineInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Laura EdwardsAbt Associates, Inc., Atlanta, Georgia, USA.
Sarah RadkeNational Institute of Health Innovation, University of Auckland, Auckland, New Zealand.
Adam S LauringSchool of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
Jill M FerdinandsInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Chao ZhangInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Young M YooInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jacob DreiherSoroka University Medical Center, Clalit Health Services, Be'er Sheva, Israel.
Gabriella Newes-AdeyiAbt Associates, Inc., Atlanta, Georgia, USA.
Eduardo Azziz-BaumgartnerInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Alicia M FryInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Arnold S MontoSchool of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
Ran BalicerClalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.
Mark G ThompsonInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mark A KatzClalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

objectivesTrivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016 to 2019. We conducted a randomised immunogenicity trial of quadrivalent recombinant influenza vaccine (RIV4) and standard-dose inactivated influenza vaccine (IIV4) among frequently and infrequently vaccinated previous cohort participants.

methodsFrom October 2019 to January 2020, we enrolled and randomly allocated HCP from two Israeli hospitals to receive IIV4 or RIV4. Hemagglutination inhibition (HAI) antibody titres against 2019-2020 vaccine reference influenza viruses were compared between vaccine groups using geometric mean titre (GMT) ratios from sera collected one-month post-vaccination and by frequency of vaccination in the past 5 years (>2 vs ≤2).

resultsAmong 415 HCP, the GMT ratio comparing RIV4 to IIV4 was 2.0 (95% confidence interval [CI] 1.7-2.7) for A(H1N1)pdm09, 1.6 (95% CI: 1.3-1.9) for A(H3N2), 1.8 (95% CI: 1.4-2.2) for B(Yamagata), and 1.1 (95% CI: 0.9-1.4) for B(Victoria). Similarly, RIV4 elicited higher HAI titres than IIV4 against all 2019-2020 vaccine reference viruses except B(Victoria) among infrequently and frequently vaccinated HCP (lower bound of GMT ratio 95% CIs ≥1.0).

conclusionRIV4 had improved immunogenicity for influenza vaccine strains among both infrequent and frequent vaccinees compared to standard-dose IIV4. CLINICAL TRIALS REGISTRATION: NCT04523324.

Indexed as

Antibodies, ViralHealth PersonnelImmunogenicity, VaccineInfluenza, HumanInfluenza VaccinesVaccines, SyntheticAdultFemaleHemagglutination Inhibition TestsHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza B virusIsraelMaleMiddle AgedAntibodies, ViralInfluenza VaccinesVaccines, InactivatedVaccines, SyntheticFlublokHealthcare personnelImmunogenicityInfluenza vaccineRecombinant

Identifiers

PMID39395753
PMCPMC11883642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.